Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma

INTRODUCTION: Erythropoiesis-stimulating agent (ESA) treatment has been associated with an increased risk of venous thromboembolism (VTE) in patients with solid tumors and with an increased risk of cardiovascular events in patients with chronic kidney disease. The ESA-related risk in patients with h...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Epidemiol
Hauptverfasser: Horváth-Puhó, Erzsébet, Suttorp, Marit M, Frederiksen, Henrik, Hoekstra, Tiny, Dekkers, Olaf M, Pedersen, Lars, Cannegieter, Suzanne C, Dekker, Friedo W, Sørensen, Henrik Toft
Format: Artigo
Sprache:Inglês
Veröffentlicht: Dove Medical Press 2018
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6167129/
https://ncbi.nlm.nih.gov/pubmed/30310329
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CLEP.S172306
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge